# US 2026/0097005 A1 · Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097005 A1
- Document ID: US20260097005A1
- Status: Published application
- Kind: A1
- Application number: 19/353,020
- Filed: 2025-10-08
- Published: 2026-04-09
- Earliest claimed: 2019-06-04
- Assignees: ADNP Kids Research Foundation
- Applicants: ADNP Kids Research Foundation
- Inventors: Sandra SERMONE; Matthew Christopher DAVIS
- Web page: https://patentgrep.com/patent/US20260097005A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 38/1709: {from mammals}
- A61K 38/18: Growth factors; Growth regulators
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a method of increasing the expression of Activity-Dependent Neuroprotector Protein (ADNP) in at least one mammalian cell showing insufficient ADNP expression levels, comprising administering to the at least one mammalian cell an effective amount of ketamine or a combination of ketamine and ADNP-Derived Neuroprotective Peptide (NAP).

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating a condition related to an insufficient Activity-Dependent Neuroprotective Protein (ADNP) expression level, the method comprising administering an effective amount of ketamine to a human subject in need of treatment for the condition related to the insufficient ADNP expression level, wherein the effective amount of ketamine is administered about every three days or about every four days.

### Claim 22 (depends on 21)

The method of claim 21, wherein the insufficient ADNP expression level is related to an insufficient expression of an ADNP gene or a Forkhead Box Protein P1 (FOXP1) gene.

### Claim 23 (depends on 22)

The method of claim 22, wherein the insufficient ADNP expression level is related to a genetic alteration of the ADNP gene or the Forkhead Box Protein P1 (FOXP1) gene.

### Claim 24 (depends on 23)

The method of claim 23, wherein the insufficient ADNP expression level is related to the genetic alteration of the ADNP gene.

### Claim 25 (depends on 21)

The method of claim 21, wherein the insufficient ADNP expression level is related to an insufficient expression level of the Activity-Dependent Neuroprotector Homeobox protein.

### Claim 26 (depends on 21)

The method of claim 21, wherein the condition is Autism Spectrum Disorder (ASD), ADNP Syndrome, Alzheimer's Disease, or Schizophrenia.

### Claim 27 (depends on 21)

The method of claim 21, wherein the insufficient ADNP expression level is related to a neurodevelopmental dysfunction, a neurological degeneration, an intellectual impairment, a learning deficit, a sensory processing disorder, a sensation-seeking behavior, a delayed speech development, a delayed language development, a neurological speech impairment, a motor dysfunction, an impaired social interaction, a urinary incontinence, an occurrence of abnormal temper tantrums, an attention deficit and hyperactivity, a sleep disturbance, an occurrence of seizures, or a combination thereof.

### Claim 28 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered with a second pharmaceutically active agent.

### Claim 29 (depends on 28)

The method of claim 28, wherein the ketamine and the second pharmaceutically active agent are administered separately or co-administered.

### Claim 30 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered intranasally, orally, topically, parenterally, intramuscularly, subcutaneously, or intravenously.

### Claim 31 (depends on 30)

The method of claim 30, wherein the effective amount of ketamine is administered intranasally.

### Claim 32 (depends on 31)

The method of claim 31, wherein the effective amount of ketamine is administered in a dose of more than about 0.5 mg/kg and less than about 20 mg/kg.

### Claim 33 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered in an aerosolized form, in a powdered form, or in a liquid form.

### Claim 34 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered in a dose of between about 0.01 mg/kg and about 5 mg/kg.

### Claim 35 (depends on 34)

The method of claim 34, wherein the effective amount of ketamine is administered in a dose of about 5.0 mg/kg.

### Claim 36 (depends on 34)

The method of claim 34, wherein the effective amount of ketamine is administered in a dose of about 0.5 mg/kg.

### Claim 37 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered about every three days.

### Claim 38 (depends on 21)

The method of claim 21, wherein the effective amount of ketamine is administered about every four days.
